Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers.

Abstract excerpt

Activating mutations in KRAS are highly relevant to various cancers, driving persistent efforts toward the development of drugs that can effectively inhibit KRAS activity. Previously, KRAS was considered 'undruggable'; however, the recent advances in our understanding of RNA and nucleic acid chemistry and delivery formulations have sparked a paradigm shift in the approach to KRAS inhibition. We are currently...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Neoplasms
• Share to Nucleic Acids